Technology ID
E-253-2011-0

Broadly Neutralizing Human Anti-HIV Monoclonal Antibody 10E8 and Related Antibodies Capable of Neutralizing Most HIV-1 Strains

Linked ID
TAB-2428
Inventors
Jinghe Huang (NIAID)
John Mascola (NIAID)
Joyce Goldstein (NIEHS)
Leo Laub (NIAID)
Mark Connors (NIAID)
Lead Inventors
Mark Connors (NIAID)
Co-Inventors
Jinghe Huang (NIAID)
John Mascola (NIAID)
Joyce Goldstein (NIEHS)
Leo Laub (NIAID)
Development Stages
Pre-clinical (in vivo)
Development Status
  • In vitro data available
  • In vivo data available (animal)
ICs
NIEHS
NIAID
Commercial Applications
  • Passive protection to prevent HIV infection
  • Passive protection to prevent mother-to-infant HIV transmission
  • Topical microbicide to prevent HIV infection
  • Gene-based vectors for anti-gp41 antibody expression
  • Therapeutic for the elimination of HIV infected cells that are actively producing virus
The uses for human anti-HIV monoclonal antibody 10E8 and its variants include passive immunization, therapeutic vaccination, and the development of vaccine immunogens. 10E8 is one of the most potent HIV-neutralizing antibodies isolated and it neutralizes up to 98% of diverse HIV-1 strains. 10E8 is specific to the membrane-proximal external region (MPER) of the HIV envelope protein gp41 and 10E8 is orthogonal to other anti-HIV antibodies. In combination with other antibodies 10E8 may provide an antibody response that neutralizes nearly all strains of HIV-1. Additionally, 10E8 effectively induces antibody-dependent cellular cytotoxicity (ADCC) indicating its potential use for therapeutic vaccine strategies. Further, 10E8 is a tool for immunogen design and validation of immunogen structure.

NIAID is currently developing certain embodiments of 10E8 for clinical use. Therefore, for some fields of use, NIH will evaluate a license applicant's capabilities and experience in advancing similar technologies through the regulatory process. This technology is not eligible for the NIH's start-up license program.
Competitive Advantages
  • One of the most potent Human broadly-neutralizing anti HIV antibodies isolated to date
  • Broad reactivity and high affinity to most HIV-1 strains
  • Activity is highly complementary to existing broadly neutralizing antibodies, such as CD4 binding site antibodies
  • Not auto-reactive

Request More Info

Licensing Contact